AU2017344040A1 - Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases - Google Patents

Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU2017344040A1
AU2017344040A1 AU2017344040A AU2017344040A AU2017344040A1 AU 2017344040 A1 AU2017344040 A1 AU 2017344040A1 AU 2017344040 A AU2017344040 A AU 2017344040A AU 2017344040 A AU2017344040 A AU 2017344040A AU 2017344040 A1 AU2017344040 A1 AU 2017344040A1
Authority
AU
Australia
Prior art keywords
active ingredient
pharmaceutical composition
cannabinoid
cannabinoids
minor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017344040A
Other languages
English (en)
Inventor
Andrea Small-Howard
Helen TURNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GBS Global Biopharma Inc
Original Assignee
GBS Global Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GBS Global Biopharma Inc filed Critical GBS Global Biopharma Inc
Publication of AU2017344040A1 publication Critical patent/AU2017344040A1/en
Priority to AU2023222872A priority Critical patent/AU2023222872A1/en
Priority to AU2025213702A priority patent/AU2025213702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017344040A 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Abandoned AU2017344040A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023222872A AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406764P 2016-10-11 2016-10-11
US62/406,764 2016-10-11
PCT/US2017/055989 WO2018071452A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023222872A Division AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2017344040A1 true AU2017344040A1 (en) 2019-04-18

Family

ID=60382587

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017344040A Abandoned AU2017344040A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2023222872A Abandoned AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A Pending AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023222872A Abandoned AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A Pending AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Country Status (8)

Country Link
US (3) US10653640B2 (https=)
EP (1) EP3525823B1 (https=)
JP (2) JP7225103B2 (https=)
CN (2) CN109963595B (https=)
AU (3) AU2017344040A1 (https=)
CA (1) CA3039413A1 (https=)
IL (1) IL265902B2 (https=)
WO (1) WO2018071452A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018205022A1 (en) 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
JP2020520966A (ja) 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
JP2021524465A (ja) 2018-05-22 2021-09-13 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１モジュレーションに使用するためのカンナビノイド及び／又はテルペン
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
AU2019413789B2 (en) * 2018-12-29 2025-05-29 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
KR20220080045A (ko) * 2019-04-24 2022-06-14 인메드 파마슈티컬스 인코포레이티드 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법
CA3144983A1 (en) * 2019-06-28 2020-12-30 Gbs Global Biopharma, Inc. Treatment of pain using allosteric modulator of trpv1
US12576093B2 (en) 2019-07-17 2026-03-17 Mannkind Corporation Pharmaceutical composition for subcutaneous administration
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20220110910A1 (en) * 2020-08-18 2022-04-14 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of cytokine release syndrome while preserving key anti-viral immune reactions
PL4124336T3 (pl) 2021-07-30 2024-02-26 Cannamedical Pharma Gmbh Plaster przezśluzówkowy obejmujący kannabinoid i/lub opioid
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
EP4408404A4 (en) * 2021-09-28 2025-10-29 Gbs Global Biopharma Inc Formulations containing cannabinoids for Parkinsonian movement disorders
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500845A (ja) 1981-06-04 1983-05-26 デラウェア・ケミカルス・コーポレーション ポンプ
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
EA003328B1 (ru) 1998-04-08 2003-04-24 Эли Лилли Энд Компани Легочная и назальная доставка ралоксифена
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CA2533400C (en) * 2001-02-14 2017-01-03 Gw Pharma Limited Cannabinoids pharmaceutical formulations
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
EP1587482A4 (en) 2003-01-31 2010-08-25 Technion Res & Dev Foundation INFLAMMATORY COMPOSITIONS AND ITS USES
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
US9066910B2 (en) 2010-04-15 2015-06-30 Steven Rosenblatt Methods and compositions of cannabis extracts
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2014145490A2 (en) * 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
CN105228602A (zh) 2013-05-24 2016-01-06 雀巢产品技术援助有限公司 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP4151234A1 (en) 2014-05-29 2023-03-22 Fresh Cut Development, LLC Stable cannabinoid formulations
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016133824A1 (en) 2015-02-16 2016-08-25 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2017193072A1 (en) * 2016-05-06 2017-11-09 Harvest Direct Enterprises Llc The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals

Also Published As

Publication number Publication date
US20250108016A1 (en) 2025-04-03
CN115887440A (zh) 2023-04-04
IL265902B1 (en) 2023-12-01
AU2023222872A1 (en) 2023-09-21
EP3525823A1 (en) 2019-08-21
US20180098948A1 (en) 2018-04-12
AU2025213702A1 (en) 2025-09-04
IL265902A (en) 2019-06-30
JP2023058599A (ja) 2023-04-25
CN109963595A (zh) 2019-07-02
EP3525823B1 (en) 2024-04-24
JP2019530751A (ja) 2019-10-24
US20200338017A1 (en) 2020-10-29
WO2018071452A1 (en) 2018-04-19
CN109963595B (zh) 2023-02-03
JP7225103B2 (ja) 2023-02-20
CA3039413A1 (en) 2018-04-19
US11980592B2 (en) 2024-05-14
IL265902B2 (en) 2024-04-01
US10653640B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
US20250108016A1 (en) Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US20240269089A1 (en) Myrcene-containing complex mixtures targeting trpv1
EP3576724B1 (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
CN101939017B (zh) 大麻素在与抗精神病药物组合中的用途
US20230087359A1 (en) Cannabinoid compositions and methods of use thereof
US20200405657A1 (en) Treatment of pain using allosteric modulator of trpv1
HK40012464A (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
HK40012464B (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
CA3234083A1 (en) Cannabinoid-containing formulations for parkinsonian movement disorders
HK40019031A (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
HK40019031B (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted